Holen Sie sich die Stockscreener-App
74.19
2.85%
-2.18
Schlusskurs vom Vortag:
$76.37
Offen:
$74.67
24-Stunden-Volumen:
601.54K
Relative Volume:
0.66
Marktkapitalisierung:
$2.53B
Einnahmen:
$55.63M
Nettoeinkommen (Verlust:
$-158.10M
KGV:
-8.811
EPS:
-8.4202
Netto-Cashflow:
$-203.94M
1W Leistung:
+2.30%
1M Leistung:
+1.97%
6M Leistung:
+4.33%
1J Leistung:
+106.20%
1-Tages-Spanne:
$73.64
$75.63
1-Wochen-Bereich:
$70.00
$76.63
52-Wochen-Spanne:
$33.40
$109.00
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
74.19 | 2.54B | 55.63M | -158.10M | -203.94M | -8.4202 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | Wedbush | Neutral |
| 2026-03-17 | Eingeleitet | TD Cowen | Buy |
| 2026-02-10 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Eingeleitet | Citigroup | Buy |
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa
Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat
Nektar (NKTR) Q2 2026 Earnings Call Transcript - AOL.com
Nektar Therapeutics Stock Historical Valuations | XTER:ITH0 - GuruFocus
Nektar Therapeutics (NKTR) exec sells shares only to cover taxes - Stock Titan
Nektar Therapeutics Stock Operating Data - GuruFocus
NKTR Stock Quote Price and Forecast - CNN
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus
Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan
Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan
NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
Piper Sandler Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance
Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan
Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan
Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - TradingView
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st
Boost Run, Nektar Therapeutics, Swarmer - TradingView
Nektar Therapeutics Q2 2026 Earnings Call Summary - Yahoo Finance
Nektar Therapeutics Boosts Cash to Over $1 Billion After Major Dilutive Equity Raises - Minichart
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo
NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary - TradingView
Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss - Stock Titan
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Cash Reaches $1.02 Billion After $373.8 Million Offering - Minichart
Nektar Therapeutics rated Strong Buy on REZPEG's promising Phase 3 trials for atopic dermatitis and alopecia areata. - Pluang
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 - The Clinical Trial Vanguard
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: R - GuruFocus
Nektar Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours - Investing.com Nigeria
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call - Benzinga
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS - MarketBeat
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nektar Therapeutics-Aktie (NKTR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ROBIN HOWARD W | President & CEO |
Aug 18 '26 |
Sale |
71.98 |
418 |
30,088 |
54,627 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):